Pharming Historical Income Statement
PHAR Stock | USD 8.68 0.14 1.64% |
Historical analysis of Pharming Group income statement accounts such as Gross Profit of 265.8 M, Other Operating Expenses of 302.7 M, Research Development of 83.2 M or Ebitda of 11.9 M can show how well Pharming Group NV performed in making a profits. Evaluating Pharming Group income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pharming Group's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Pharming Group NV latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pharming Group NV is a good buy for the upcoming year.
Pharming |
About Pharming Income Statement Analysis
Pharming Group NV Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pharming Group shareholders. The income statement also shows Pharming investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Pharming Group Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Pharming Group NV generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pharming Group NV. It is also known as Pharming Group overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Pharming Group's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year.
2022 | 2023 | 2024 | 2025 (projected) | Total Operating Expenses | 169.8M | 225.5M | 259.3M | 272.3M | Cost Of Revenue | 17.6M | 25.2M | 29.0M | 15.2M |
Pharming Group income statement Correlations
Click cells to compare fundamentals
Pharming Group Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pharming Group income statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Depreciation And Amortization | 8.3M | 19.6M | 13.2M | 15.9M | 18.3M | 19.2M | |
Interest Expense | 6.4M | 5.9M | 5.4M | 6.0M | 6.9M | 6.4M | |
Selling And Marketing Expenses | 55.5M | 56.8M | 85.8M | 6.8M | 7.8M | 7.4M | |
Total Revenue | 228.4M | 189.9M | 205.6M | 245.3M | 282.1M | 296.2M | |
Gross Profit | 203.1M | 169.7M | 188.1M | 220.1M | 253.1M | 265.8M | |
Other Operating Expenses | 146.3M | 176.9M | 187.4M | 250.7M | 288.3M | 302.7M | |
Operating Income | 82.1M | 27.8M | 18.2M | (4.9M) | (5.6M) | (5.3M) | |
Ebit | 83.8M | 29.2M | 20.3M | (6.0M) | (7.0M) | (7.3M) | |
Research Development | 41.5M | 67.2M | 52.5M | 68.9M | 79.3M | 83.2M | |
Ebitda | 92.1M | 48.8M | 33.5M | 9.9M | 11.4M | 11.9M | |
Cost Of Revenue | 25.3M | 20.2M | 17.6M | 25.2M | 29.0M | 15.2M | |
Total Operating Expenses | 121.0M | 156.7M | 169.8M | 225.5M | 259.3M | 272.3M | |
Income Before Tax | 47.5M | 22.0M | 15.0M | (12.0M) | (13.8M) | (14.5M) | |
Total Other Income Expense Net | (18.3M) | (4.8M) | (3.2M) | (7.1M) | (6.4M) | (6.7M) | |
Net Income | 37.7M | 16.0M | 13.7M | (10.5M) | (12.1M) | (12.7M) | |
Income Tax Expense | 6.8M | 6.8M | 1.3M | (1.5M) | (1.3M) | (1.3M) | |
Selling General Administrative | 14.4M | 35.3M | 46.0M | 80.7M | 92.8M | 97.4M | |
Tax Provision | 5.6M | 6.0M | 1.3M | (1.5M) | (1.7M) | (1.8M) | |
Net Interest Income | (4.6M) | 7.3M | (978K) | (2.4M) | (2.8M) | (2.9M) | |
Interest Income | 626K | 12.6M | 85K | 3.7M | 4.2M | 2.8M | |
Net Income From Continuing Ops | 33.0M | 13.5M | 13.7M | (10.5M) | (12.1M) | (11.5M) | |
Reconciled Depreciation | 7.3M | 16.5M | 13.2M | 15.9M | 18.3M | 10.7M | |
Net Income Applicable To Common Shares | 36.2M | 33.0M | 13.5M | 13.7M | 15.7M | 8.3M |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.